Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive
Mississauga, ON, Canada L5L 4M1 Glenn Neumann
tel: (905) 569-2265 fax: (905) 569-9231 Investor Relations
www.vasogen.com (905) 569-9065
[email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Andre Berard Joins Vasogen's Board of Directors
Toronto, Ontario (November 7, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) is
pleased to announce the appointment of Mr. Andre Berard to its Board of
Directors. Mr. Berard currently serves as Chairman of the Board and Chief
Executive Officer of the National Bank of Canada.
Mr. Berard, who has spent over four decades with the Bank, was appointed
President and Chief Executive Officer in 1989 and elected Chairman of the Board
in 1990. Mr. Berard also serves on the Boards of other companies including
Noranda Inc., Groupe TVA Inc., Groupe Saputo Inc., and Societe financiere
Bourgie Inc. He is a Director of Natcan International Trade Finance and
Investment Co. Ltd., Natcan Finance (Asia) Ltd., the Macdonald Stewart
Foundation, and acts as a non-voting member of the board of the Banque regionale
d'escompte et de depot (BRED) in France. Mr. Berard sits on the Advisory
Committee to the Prime Minister on the Business/Government Executive Exchange
Program and is a member of the Policy Committee of the Business Council on
National Issues, the Conseil des gouverneurs associes of the Universite de
Montreal, the Jeune Chambre de commerce de Montreal, and the Chambre de commerce
du Quebec.
Mr. Berard has received an honorary doctorate from the University of Ottawa and
from Ecole des Hautes Etudes Commerciales, the business school of the Universite
de Montreal. He was made an Officer of the Order of Canada, an Officer of the
Ordre national du Quebec, and has received the Ordre de Saint-Jean. Committed to
serving the community, Mr. Berard has chaired many fundraising campaigns and has
served as honorary chairman of the Montreal Heart Institute Research Fund.
"We are delighted to have Andre Berard accept a position on Vasogen's Board of
Directors," commented Dr. William Cochrane, Chairman of Vasogen. "With over 40
years' experience in the financial industry, Mr. Berard adds to the Board's
depth of business experience, financial expertise, and network of contacts that
will benefit the Company as we continue to advance the commercial development of
our products."
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made. The Toronto
Stock Exchange has not reviewed and does not accept responsibility for the
adequacy or the contents of this news release.
